

Details of Q3 FY24 Quarterly Report, Appendix 4C & Webinar

Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) advises that it will release its Q3 FY24 Quarterly Activities Report & Appendix 4C on Tuesday, 23 April 2024.

The Company will host an investor webinar via Zoom with **CEO Dr Luke Reid** and **SVP, Therapeutics Prof. Trent Munro** at 12:00pm (midday) AEST on Tuesday, 23 April 2024.

Quarterly Investor Webinar

Presenting: CEO, Dr Luke Reid and SVP, Therapeutics Prof. Trent Munro

Time: 12:00pm (midday) AEST on Tuesday, 23 April 2024

To register: [Microba Q3 FY24 Investor Webinar Registration](#)

Investor Q&As

Investors can submit questions via the Q&A functions on Zoom during the webinar. The recording will be made available on the Company’s Investor Hub shortly after the webinar concludes at <https://ir.microba.com/link/8r6X5y>

Investors with complete Microba Investor Hub accounts can also submit questions prior to the webinar via Microba’s interactive investor platform following this link: <https://ir.microba.com/link/8r6X5y>

This announcement has been authorised for release by the Chair and CEO.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer

luke.reid@microba.com

<https://ir.microba.com/welcome>

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com



JOIN MICROBA'S INTERACTIVE INVESTOR HUB

Visit ir.microba.com/welcome for Microba's interactive Investor Hub

Microba Life Sciences Ltd ABN 82 617 096 652 Level 10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621